Article Text

Download PDFPDF

272 Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from ovarian cancer: a preliminary single-center experience from saudi arabia
  1. I Al-Badawi
  1. King Faisal Specialist Hospital and Research Center, Obstetrics and Gynecology, Riyadh, Saudi Arabia


Objectives To report our preliminary single-center experience with cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of peritoneal carcinomatosis (PC) arising from ovarian cancer.

Methods From 2016–2018, 23 patients underwent CRS+HIPEC. CRS was performed with standard peritonectomy procedures and visceral resections directed toward complete elimination of tumors. HIPEC was performed with either cisplatin (50 mg/m²) plus doxorubicin (15 mg/m²), or single-agent cisplatin (100 mg/m²), and allowed to circulate in the abdominopelvic cavity for 90 min at 41.0–42.2°C.

Results Almost all PC cases were primary disease presentations (61.9%) and had high-grade papillary serous histology (90.5%). Cytoreduction completeness (CC-0/1) was achieved in all patients with a median peritoneal cancer index (PCI) of 12±6.3 (range: 3–30). Combination cisplatin+doxorubicin HIPEC chemotherapy was used in 14 patients (66.7%). The median estimated blood loss and hospital stay were 1200±350 mL (range: 800–4500) and 14±5.7 days (range: 8–47), respectively. Major postoperative Clavien-Dindo grade III/IV complications occurred in 3 patients (14.3%), and none developed HIPEC chemotherapy-related toxicities. The median overall survival (OS) and disease-free survival (DFS) after CRS+HIPEC were 18±2.4 and 9.8±3.2 months, respectively. The median follow-up time was 13 months (range: 8–42). In a univariate analysis, patients with CC-0, <12 PCI score and primary PS presentation had statistically higher median 5-year DFS and OS (P<0.05). In a multivariate analysis, CC-0 was shown to be an independent significant prognostic factor for OS (P<0.05).

Conclusions CRS+HIPEC appears to be feasible, safe, and yields survival oncological benefits in patients with PS originating from ovarian cancer.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.